Your cart is currently empty!
TESAMORELIN 10MG
Tesamorelin Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a C-terminal modification for stability. Preclinical studies in cell cultures and animal models indicate that Tesamorelin stimulates pituitary somatotrophs to release endogenous growth hormone (GH) in a pulsatile manner, leading to elevated circulating GH and IGF-1 levels without…
33 in stock
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 44 amino acids with a C-terminal modification for stability. Preclinical studies in cell cultures and animal models indicate that Tesamorelin stimulates pituitary somatotrophs to release endogenous growth hormone (GH) in a pulsatile manner, leading to elevated circulating GH and IGF-1 levels without significant disruption of the natural feedback axis.[1][2]
Key Research Areas
- Growth Hormone Secretion & Pulsatile Dynamics – In rodent and primate models, Tesamorelin has been shown to induce physiological GH pulses, mimicking natural episodic secretion and supporting research into the GH axis in metabolic and aging paradigms.[3][4]
- Metabolic & Body Composition Effects – Preclinical investigations demonstrate enhanced lipolysis, reduced visceral fat accumulation, and improved lipid profiles in animal models of metabolic dysfunction and growth hormone deficiency.[5][6]
- Tissue Maintenance & Anabolic Pathways – Animal studies suggest Tesamorelin supports protein synthesis, nitrogen retention, and connective tissue integrity through elevated GH/IGF-1 signaling in models of aging or injury.[7][8]
Product Specifications
| CAS Number | 218949-78-5 |
| Molecular Formula | C221H366N72O67S |
| Molar Mass | 5135.89 g/mol |
| Sequence | Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 |
| Synonyms | TH-9507, GHRH (1-44) NH2, Tesamorelin Acetate |
| Purity | ≥99% (HPLC) |
| Form | Lyophilized powder |
| Storage | −20°C (long-term), 2–8°C (reconstituted) |
| Solubility | Bacteriostatic water or sterile saline for reconstitution |
References
- 1. Merriam GR, et al. Growth hormone-releasing hormone: a review of its use in adults with growth hormone deficiency. Drugs. 2003. PubMed
- 2. Falutz J, et al. Metabolic effects of a growth hormone-releasing hormone analog in HIV-infected men with excess visceral fat. J Clin Endocrinol Metab. 2007. PubMed
- 3. Koutkia P, et al. Growth hormone-releasing hormone (GHRH) in HIV-associated lipodystrophy. J Clin Endocrinol Metab. 2004. PubMed
- 4. Stanley TL, et al. Effects of tesamorelin on fat metabolism in HIV-infected patients with abdominal fat accumulation. J Clin Endocrinol Metab. 2012. PubMed
- 5. Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in patients with HIV lipodystrophy. N Engl J Med. 2010. PubMed
- 6. Veldhuis JD, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. Growth Horm IGF Res. 2010. PubMed
- 7. Sigalos JT, et al. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed
- 8. Stanley TL, et al. Tesamorelin in HIV-associated lipodystrophy: effects on body composition and metabolic parameters. J Clin Endocrinol Metab. 2011. PubMed
.specs-table table { width: 100%; max-width: 600px; border-collapse: collapse; margin: 20px 0; }
.specs-table td { padding: 10px; border: 1px solid #ddd; }
.specs-table td:first-child { background: #f5f5f5; font-weight: 600; }
.references { line-height: 1.7; }
@media (max-width: 600px) {
.specs-table table, .specs-table td { display: block; width: 100%; }
.specs-table td:first-child { background: #eee; }
}






